Secondary tabs
Contact details
David Price dprice@opri.sg
Main
Publications
Data source publications
Studies
List of studies that have been conducted using the data source
- Demographic and Clinical Characteristics of Severe Asthma Patients Worldwide
- The Impact of Exacerbation Burden on Lung Function Trajectory in a Broad Asthma Population and Severe Asthma Population (Exacerbation and lung function trajectory)
- Biologics in severe asthma: utilization patterns, causes for discontinuation and switches
- The Characterization and Comparison of Eosinophilic and Non-eosinophilic Phenotypes of Severe Asthma
- Biomarker Relatability in the International Severe Asthma Registry (BRISAR)
- Hidden Severe Asthma in Primary Care versus ISAR Cohort
- Impact of Initiating Biologics In Patients on Long-Term OCS Or Frequent Rescue Steroids (GLITTER)
- Onset of asthma in severe asthma patients (PATH)
- Effectiveness across severe asthma biologic classes (Anti-IL-5 vs Anti IgE) in patients eligible for both (FIRE)
- Defining and Characterizing Responders to Biologic Treatment (BEAM)
- Biologic Usage Patterns, Clinical Outcomes and Healthcare Resource Utilization (CLEAR)
- Characteristics of type 2 asthma phenotypes and oral corticosteroid (OCS) use in the International Severe Asthma Registry (ISAR) (STAR)
- CLinical oUtcomes before and after biologic treatMent by bIologic class, by iNdividuAl biologic, and by subgroups of baseliNe characTeristics (LUMINANT)
- ImPact of comoRbidity In Severe asthMa patients (PRISM)
- EffectIveness of bioloGics (by classes) in patieNts with dIfferent combination of T2 biomarkErs (IGNITE)
- PhEnotypic Characteristics, coMorBidities and response to thErapeutic inteRventions associated with non-type 2 asthma (EMBER)
- Exploring different composite definitions of responders and non-responders to biologic treatment for severe asthma (FULL BEAM)
- Impact of biologic initiation on steroid burden and new-onset of potentially OCS-related outcomes in patients with severe asthma (SOLAR)
- Patient characteristics, treatment patterns, clinical outcomes, and health care resource utilization in severe asthma subgroups: A retrospective analysis of the International Severe Asthma Registry (EVEREST)
- A global evaluation of the economic impact of time to initiation of biologic treatment of severe asthma patients
- ENLIGHTEN: Assessment of quality improvement in the International Severe Asthma Registry
- Assessing the impact of earlier access to biologics on remission and natural course of asthma (GLEAM)
- Associations between biological and clinical response following treatment with anti-IL5/5R biologics (FLAME)